Legend Biotech names former Novartis executive as CEO and Vera reports positive kidney drug trial results
Legend Biotech has appointed Ingrid Zhang, a former Novartis executive, as its chief executive, while Vera announced encouraging outcomes from a two-year kidney disease study.
Ingrid Zhang will lead Legend Biotech after succeeding Ying Huang, who stepped down in July. Zhang previously held a senior role at Novartis. Separately, Vera said its newly launched therapy stabilized kidney function and lowered the risk of death and complications in a two-year trial involving patients with a chronic autoimmune kidney condition. The company plans to pursue full regulatory approval based on these findings.
Why it matters
Leadership shifts and promising trial data can influence biotech market dynamics and future patient treatments.
In this story
Legend BiotechIngrid ZhangCEO appointmentkidney drugclinical trialNovartisregulatory approval
